SPECIAL FEATURE — Noxilizer’s NO₂ sterilization is featured as one of the ways to improve parenteral drug delivery, including prefilled syringes

Elon Musk just warned the world that Artificial Intelligence (AI) is dangerous and has the potential to destroy civi­lization. Yet, AI will likely be used in nearly every industry, and the biopharma industry is no exception. A new report from VisionGain1 shows that 75% of pharmaceutical organizations want to use automated solutions more frequently, driven by injectable drug delivery. The report found that pharmaceutical production lines are challenged by customized dosages and products such as prefilled syringes (PFS). Therefore, manufacturers are searching for equipment that can handle the greater range of formats generated in smaller batch sizes, while still reducing downtime. Additionally, the popularity of injectables has increased the focus on sterility and product safety, an area where experts see AI having an impact.

While the industry is just at the precipice of discovering what AI can do for injectable delivery, this exclusive Drug Development & Delivery annual report highlights the strides that companies are currently making toward improving dose accuracy, integrating design safety, and accelerating time to market…

Scroll to Top